Physician profile
Edgar C Baselli
NPI 1255418885
$2,060.17
in general payments reported to CMS, 2019-2025
26 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $114 · 2021: $236 · 2022: $458 · 2023: $436 · 2024: $238 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $434.59 | 2019-2023 | Myrbetriq |
| Abbvie INC. | $255.68 | 2019-2023 | Lupron Depot |
| Coloplast Corp | $249.54 | 2022-2025 | Speedicath |
| Teleflex LLC | $163.94 | 2021-2025 | Barrigel, Urolift |
| Janssen Biotech, INC. | $145.18 | 2021-2023 | |
| Pfizer INC. | $140.72 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $99.72 | 2023-2025 | Orgovyx |
| Merck Sharp & Dohme LLC | $76.96 | 2020-2024 | Keytruda, Lynparza |
| Allergan, INC. | $73.52 | 2019-2021 | |
| Verity Pharmaceuticals INC. | $53.27 | 2022-2025 | Trelstar |
| Ambu INC. | $40.28 | 2021-2022 | |
| Urovant Sciences INC | $37.32 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $35.75 | 2019 | |
| Rochester Medical Corporation | $31.78 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.43 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $29.30 | 2023 | Spaceoar Vue System - 10ml |
| Tolmar, INC. | $26.94 | 2023 | |
| Laborie Medical Technologies Corp. | $21.60 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Myovant Sciences INC. | $21.20 | 2022 | |
| Accord Healthcare, INC. | $17.52 | 2022 | |
| Tempus Ai, INC | $16.93 | 2024 | |
| Immunitybio, INC. | $16.23 | 2024 | |
| Axonics, INC. | $14.31 | 2021 | |
| Mission Pharmacal Company | $14.31 | 2024 | Uribel Tabs |
| Metuchen Pharmaceuticals | $12.15 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Baselli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.